1Departments of Medicine, Microbiology and Immunology, University of California at San Francisco, San Francisco, CA, USA
OPEN PEER REVIEW
REVIEWER STATUS
Abstract
While highly active anti-retroviral therapy has greatly improved the lives of HIV-infected individuals, current treatments are unable to completely eradicate the virus. This is due to the presence of HIV latently infected cells which harbor transcriptionally silent HIV. Latent HIV does not replicate or produce viral proteins, thereby preventing efficient targeting by anti-retroviral drugs. Strategies to target the HIV latent reservoir include viral reactivation, enhancing host defense mechanisms, keeping latent HIV silent, and using gene therapy techniques to knock out or reactivate latent HIV. While research into each of these areas has yielded promising results, currently no one mechanism eradicates latent HIV. Instead, combinations of these approaches should be considered for a potential HIV functional cure.
Corresponding author:
B. Matija Peterlin
Competing interests:
The authors declare that they have no competing interests.
Grant information:
This work was supported by National Institutes of Health grants U19 AI096113 (Martin Delaney Collaboratory of AIDS Researchers for Eradication [CARE] Center Grant, David Margolis, PI), P50 GM082250 (HARC Center Grant, Alan Frankel and Nevan Krogan, coPIs) and AI1049104 (to B.M.P.).
In the twenty years since the implementation of highly active anti-retroviral therapy (HAART), the overall face of HIV as a global health issue has changed1. HAART—composed of a cocktail of anti-retroviral drugs which target proteins expressed at different steps in the HIV replication cycle—can affect only cells that harbor actively replicating virus. HIV+ individuals are able to live fairly normal lives on maintenance HAART, with minimal side effects. Nevertheless, the effects of HIV infection continue to be evident in these suppressed individuals, who continue to suffer from a number of metabolic, immunologic, and neurologic co-morbidities2. Thus, despite reducing plasma viremia below detection limits, the virus is not eliminated. There is evidence that low levels of replication occur in suppressed individuals, primarily in tissue reservoirs; however, this is not reflected in systemic plasma viremia in these individuals3,4. HAART requires life-long administration. Following even brief treatment interruption, HIV rebounds rapidly from its reservoirs5–7. Goals of the present research are to eliminate, suppress permanently, or render cells inhospitable to the hidden HIV in infected individuals.
Research efforts to understand and target HIV reservoirs have focused on four main categories outlined in this review (Figure 1): first, reactivation of latent HIV by capitalizing on the ability of host cellular activation signals and transcription factors (TFs) to ‘shock’ the virus out of hiding; second, killing of reactivated HIV by strengthening the immune system, which has been crippled by the infection; third, keeping latent reservoirs permanently suppressed; and, finally, targeting HIV and CD4+ T cells, which are the primary host cells for the virus, via new gene therapy approaches.
Figure 1. Four main approaches that target the latent reservoir of HIV
Four research areas, which reactivate HIV (1. shock), eliminate HIV (2. kill), silence HIV (3. silence), or alter the immune system to resist HIV (4. gene therapy) should contribute to the functional or complete cure of HIV in infected individuals. Within each area are individual components of that therapy. They can be applied individually or in combinations, which should decrease their doses and deleterious effects. Most likely, there will be additional approaches in the future.
Shock
Chronic infection by HIV is characterized by severe depletion of CD4+ T cells and continuing inflammation, which contribute to HIV-associated co-morbidities2. Continued exposure to inflammatory cytokines exhausts the immune system. It also elevates the expression of the receptors programmed death 1 (PD-1)8 and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)9 on T cells. Blockade of these molecules is used as a treatment for solid tumors10 and could reinvigorate exhausted T cells in HIV+ patients11. These individuals also produce elevated levels of inhibitory cytokines interleukin (IL)-10 and transforming growth factor–beta (TGF-β)12,13. Indeed, blocking IL-10 results in increased T cell activity in a hepatitis C infection model14,15.
Growth factor therapy, including treatment with IL-2, -7, or -15, is being explored as a means to stimulate T cell recovery. IL-2 and IL-7 are important T cell growth and proliferation factors. Infusion with IL-2 and IL-7 results in enhanced T cell production and memory T cell proliferation16–18. IL-15 enhances cytotoxic CD8+ T lymphocyte (CTL) and natural killer (NK) cell activity in vitro. Indeed, the IL-15 super-agonist ALT-803 is currently in preclinical trials19.
Latent HIV is primarily found in resting CD4+ T cells in the periphery. Resting cells have low levels of cellular TFs, which are also required for HIV replication, including NF-κB, P-TEFb, and CDK1120,21. Among the first examined latency reversing agents (LRAs) were histone deacetylase inhibitors (HDACis) and BET bromodomain inhibitors (BETis), which induce chromatin stress and induce the release of positive transcription elongation factor b (P-TEFb) from its repressive complex22. HDACis—such as panobinostat23, romidepsin24, SAHA25, and valproic acid26—and BETis—such as JQ127—all reactivate HIV in cell line models of latency. However, they do not work in human primary resting infected T cells28,29 because they contain very low levels of necessary TFs20,21. Thus, clinical trials with SAHA resulted in only a modest and transient reactivation of HIV30, making it an impractical mono-therapy for HIV reactivation.
Since HDACis and BETis do not increase levels of required TFs, some activation of CD4+ T cells is required. Indeed, protein kinase C (PKC) agonists, such as prostratin31 and bryostatin32, and the MAPK agonist procyanidin33,34 can reactivate HIV in cell line models and primary CD4+ T cells. However, prostratin is toxic at therapeutic levels, leading to muscle pain, respiratory distress, and hypertension. Bryostatin, derived from a marine animal, Bugula neritina, not only has similar side effects but is also cost prohibitive to manufacture. Because of these limitations, a number of synthetic analogues of prostratin and bryostatin with reduced toxicity in vitro are being developed35–37. Ingenols, which are purified from Euphorbia plants, represent additional PKC agonists of interest. Native and chemically modified ingenols reactivate HIV in cell lines and primary T cells38–40. These PKC agonists also increase cellular levels of necessary TFs38. Thus, select MAPK and PKC agonists represent attractive candidates to reactivate latent HIV.
Combining several of these approaches has the greatest potential to purge the viral reservoir. Indeed, lower doses of a T cell activator and an LRA (HDACi or BETi) can be administered for increased potency and reduced pro-inflammatory responses41–43. Further understanding of HIV integration, transcription, and reactivation, as well as host cell behaviors, will inform optimal combinations of activators and LRAs.
Kill
Strategies to remove HIV by enhancing the killing by CTL and NK cells44 or via broadly neutralizing antibodies (bNAbs) represent the second major field of research in HIV eradication. It is also important to investigate kill strategies in the context of the aforementioned shock therapies because many of the treatments proposed to reactivate latent HIV also dampen CTL function45, which is already impaired in HIV+ individuals11.
Using modified cytomegalovirus (CMV), a live vaccine expressing several simian immunodeficiency virus (SIV) antigens, was found to protect rhesus macaques against viral challenge46–48. Vaccinated animals initially appeared to be infected; however, they gained protection against SIV and showed enhanced effector T cell function against viral antigens.
Another approach involves bNAbs49. Following infection, anti-HIV antibodies are abundant in HIV+ patients; however, owing to the ability of the virus to mutate, the majority of them fail to eliminate the virus. bNAbs are the exception, in that they recognize many clades of HIV as well as escape mutants of the virus. In several studies, they not only neutralized virions released from activated CD4+ T cells from patients50 but also reduced the viral rebound following HIV reactivation in a humanized mouse model51. However, even the most potent bNAbs are each only effective against a narrow subset of HIV clinical isolates, suggesting that effective bNAb approaches may require a combination of several bNAbs52. A second antibody approach utilizes bispecific antibodies, wherein one arm of the Fab portion of the antibody recognizes HIV envelope and the second arm recognizes CD3, making the cell vulnerable to CTL-mediated killing.
Finally, in an effort to achieve more effective killing, chimeric antigen receptors (CARs), which increase T cell receptor avidity and activation, are being explored. They can be engineered to recognize specific viral proteins; CARs against CD19, which is a B cell receptor, led to an astounding 90% remission rate in acute leukemia53,54. However, one caveat to CARs is that these cells are long-lived and can have substantial off-target effects.
Silence
The success of HAART has demonstrated that keeping the virus suppressed results in markedly healthier individuals. Resting infected cells do not produce HIV. Thus, these strategies rely on reducing T cell activation, which should also reduce the HIV-associated inflammation found in chronically infected individuals2. JAK and STAT molecules are important signaling molecules associated with many cytokine receptors. Ruxolitinib and tofacitinib, two JAK inhibitors that are approved for the treatment of rheumatoid arthritis and myelofibrosis, were tested against HIV, HIV2, and simian HIV (SHIV). They inhibited HIV reactivation55, and, furthermore, ruxolitinib attenuated encephalitis symptoms in infected humanized mice56. Cyclosporine A, an immunosuppressant used primarily to prevent transplant rejection57, inhibits T cell proliferation by blocking IL-2 signaling in T cells58. Infected patients treated with cyclosporine A had some T cell recovery59 but limited suppression of HIV replication60,61.
The inhibitor didehydro-cortistatin A (dCA) acts via a suppressive mechanism that primarily targets HIV transcription. dCA binds to the basic domain in the HIV regulatory protein Tat, inhibits its interactions with the RNA response element TAR, and prevents its activation of HIV transcription62. dCA inhibits HIV reactivation in cell lines, primary cells, and peripheral blood mononuclear cells (PBMCs) from HAART-suppressed patients62. Furthermore, dCA may also contribute to continued HIV suppression by inhibiting inflammatory cytokine expression63.
Gene therapy
Recently, a number of groups have taken advantage of cutting edge gene therapy approaches to HIV cure. However, as with any gene therapy approach, the barriers include delivery, specificity, off-target effects, costs, and ethical concerns.
The single case of successful HIV cure was achieved by the reconstitution of the patient’s immune system with donor bone marrow containing a natural mutation in the CCR5 HIV co-receptor64. This patient was treated for acute leukemia with several courses of total lymphoid irradiation followed by two separate bone marrow transplantations. Attempts to replicate this therapy used the Zn++ finger nuclease65 and more recently CRISPR/Cas9 targeting of CCR5 to induce the delta 32 mutation in patients’ own hematopoietic cells66,67, which were then returned to the host. Since only mature cells were used, the effects of these manipulated cells were not permanent65. Recent work using CRISPR/Cas9 to target the second HIV co-receptor, CXCR4, has also yielded promising results68,69.
While HIV and SIV are highly related viruses, HIV cannot infect non-human primates, as their restriction factors block HIV infection more effectively than their human counterparts70. Therefore, altering human restriction factors to behave like their simian counterparts represents an attractive strategy. One such factor is TRIM5. Of special interest is TRIM5 from owl monkeys, which is linked in frame to cyclophilin A, and this fusion protein blocks HIV71. Using lentiviral vectors to deliver Trim-Cyp has blocked HIV effectively in cell lines and primary T cells72. Additionally, it has been used successfully in a triple combination anti-HIV lentiviral vector approach in an infected humanized mouse model73.
Recently, CRISPR/Cas9 technology has emerged as the most versatile and effective gene therapy approach. Using a DNA targeting strategy utilized by bacterial CRISPR, any number of specific guide RNAs can be loaded into the Cas9 protein to target specific areas of DNA for knock out or knock in of genes74. Similarly, this technology has been used to knock out and reactivate latent HIV. Targeting various regions of the HIV LTR inactivated the virus in infected cell lines75 and prevented their reinfection76. However, viral target sequences can mutate, and HIV LTR-specific guide RNA can fail to recognize and target the mutant sequences, preventing long-term eradication by this method77. To reactivate HIV, a defective Cas9 protein (dCas9) is used, which is fused to four copies of the herpes simplex VP16 activation domain (VP64) or a synergistic activation mediator (SAM) complex. Again, guide RNAs bring these dCas9 activators to the initiated transcription machinery. This targeting results in potent reactivation in latently infected cell lines78–80.
Summary
Although HIV infection in the era of HAART has become a manageable chronic infection, problems with adherence to drug regiment, co-morbidities, and the emergence of drug resistance emphasize the need for continued research into HIV cure. Since the barrier to cure is the HIV reservoir, targeting this persistent virus is critical. The approaches detailed in this review represent a spectrum of the current research: however, eliminating the remaining 106 to 108 latently infected cells81 will require a combination of approaches. Mechanisms, such as HIV reactivation, will reveal hidden virus. However, the severely crippled immune system and further decreased CTL function indicate that it must be paired with the boosting of anti-viral host defenses. Likewise, keeping latent HIV in a suppressed state could keep HIV+ patients relatively healthy but less able to resist other infections and/or cancer. Using gene therapy to create a parallel immune system, where cells resist HIV infection, could complement all other approaches but is not scalable or affordable in resource-poor countries. While none of these approaches represent the eradication of HIV, combining several treatment modalities could bring us closer to a functional cure, where prolonged HAART-free and disease-free intervals would be achieved in infected patients.
Competing interests
The authors declare that they have no competing interests.
Grant information
This work was supported by National Institutes of Health grants U19 AI096113 (Martin Delaney Collaboratory of AIDS Researchers for Eradication [CARE] Center Grant, David Margolis, PI), P50 GM082250 (HARC Center Grant, Alan Frankel and Nevan Krogan, coPIs) and AI1049104 (to B.M.P.).
Acknowledgements
We thank Koh Fujinaga and Wei Shao for helpful discussions.
Faculty Opinions recommended
References
1.
UNAIDS: AIDS by the numbers 2015. Joint United Nations Programme on HIV/AIDS (UNAIDS).
2015. Reference Source
2.
Marin B, Thiébaut R, Bucher HC, et al.:
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.
AIDS.
2009; 23(13): 1743–53. PubMed Abstract
| Publisher Full Text
| Free Full Text
3.
Buzón MJ, Massanella M, Llibre JM, et al.:
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
Nat Med.
2010; 16(4): 460–5. PubMed Abstract
| Publisher Full Text
5.
Chun TW, Stuyver L, Mizell SB, et al.:
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.
Proc Natl Acad Sci U S A.
1997; 94(24): 13193–7. PubMed Abstract
| Publisher Full Text
| Free Full Text
6.
Finzi D, Hermankova M, Pierson T, et al.:
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
Science.
1997; 278(5341): 1295–300. PubMed Abstract
| Publisher Full Text
7.
Wong JK, Hezareh M, Günthard HF, et al.:
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.
Science.
1997; 278(5341): 1291–5. PubMed Abstract
| Publisher Full Text
9.
Kaufmann DE, Kavanagh DG, Pereyra F, et al.:
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction.
Nat Immunol.
2007; 8(11): 1246–54. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
12.
Renga B, Francisci D, D'Amore C, et al.:
HIV-1 infection is associated with changes in nuclear receptor transcriptome, pro-inflammatory and lipid profile of monocytes.
BMC Infect Dis.
2012; 12: 274. PubMed Abstract
| Publisher Full Text
| Free Full Text
13.
Yadav A, Collman RG:
CNS inflammation and macrophage/microglial biology associated with HIV-1 infection.
J Neuroimmune Pharmacol.
2009; 4(4): 430–47. PubMed Abstract
| Publisher Full Text
14.
Brooks DG, Ha SJ, Elsaesser H, et al.:
IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection.
Proc Natl Acad Sci U S A.
2008; 105(51): 20428–33. PubMed Abstract
| Publisher Full Text
| Free Full Text
15.
Rigopoulou EI, Abbott WG, Haigh P, et al.:
Blocking of interleukin-10 receptor--a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus.
Clin Immunol.
2005; 117(1): 57–64. PubMed Abstract
| Publisher Full Text
16.
Levy Y, Lacabaratz C, Weiss L, et al.:
Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.
J Clin Invest.
2009; 119(4): 997–1007. PubMed Abstract
| Publisher Full Text
| Free Full Text
17.
Scripture-Adams DD, Brooks DG, Korin YD, et al.:
Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype.
J Virol.
2002; 76(24): 13077–82. PubMed Abstract
| Publisher Full Text
| Free Full Text
18.
Lévy Y, Sereti I, Tambussi G, et al.:
Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study.
Clin Infect Dis.
2012; 55(2): 291–300. PubMed Abstract
| Publisher Full Text
| Free Full Text
| Faculty Opinions Recommendation
20.
Bartholomeeusen K, Xiang Y, Fujinaga K, et al.:
Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein.
J Biol Chem.
2012; 287(43): 36609–16. PubMed Abstract
| Publisher Full Text
| Free Full Text
21.
Yu W, Ramakrishnan R, Wang Y, et al.:
Cyclin T1-dependent genes in activated CD4+ T and macrophage cell lines appear enriched in HIV-1 co-factors.
PLoS One.
2008; 3(9): e3146. PubMed Abstract
| Publisher Full Text
| Free Full Text
22.
Bartholomeeusen K, Fujinaga K, Xiang Y, et al.:
Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription.
J Biol Chem.
2013; 288(20): 14400–7. PubMed Abstract
| Publisher Full Text
| Free Full Text
23.
Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, et al.:
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
Hum Vaccin Immunother.
2013; 9(5): 993–1001. PubMed Abstract
| Publisher Full Text
| Free Full Text
24.
Wei DG, Chiang V, Fyne E, et al.:
Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
PLoS Pathog.
2014; 10(4): e1004071. PubMed Abstract
| Publisher Full Text
| Free Full Text
| Faculty Opinions Recommendation
25.
Contreras X, Schweneker M, Chen CS, et al.:
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
J Biol Chem.
2009; 284(11): 6782–9. PubMed Abstract
| Publisher Full Text
| Free Full Text
26.
Routy JP, Tremblay CL, Angel JB, et al.:
Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.
HIV Med.
2012; 13(5): 291–6. PubMed Abstract
| Publisher Full Text
27.
Boehm D, Calvanese V, Dar RD, et al.:
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.
Cell Cycle.
2013; 12(3): 452–62. PubMed Abstract
| Publisher Full Text
| Free Full Text
28.
Spina CA, Anderson J, Archin NM, et al.:
An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients.
PLoS Pathog.
2013; 9(12): e1003834. PubMed Abstract
| Publisher Full Text
| Free Full Text
29.
Blazkova J, Chun TW, Belay BW, et al.:
Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4+ T cells from infected individuals receiving effective antiretroviral therapy.
J Infect Dis.
2012; 206(5): 765–9. PubMed Abstract
| Publisher Full Text
| Free Full Text
31.
Korin YD, Brooks DG, Brown S, et al.:
Effects of prostratin on T-cell activation and human immunodeficiency virus latency.
J Virol.
2002; 76(16): 8118–23. PubMed Abstract
| Publisher Full Text
| Free Full Text
32.
Pérez M, de Vinuesa AG, Sanchez-Duffhues G, et al.:
Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.
Curr HIV Res.
2010; 8(6): 418–29. PubMed Abstract
| Publisher Full Text
33.
Hori T, Barnor J, Huu TN, et al.:
Procyanidin trimer C1 derived from Theobroma cacao reactivates latent human immunodeficiency virus type 1 provirus.
Biochem Biophys Res Commun.
2015; 459(2): 288–93. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
35.
Beans EJ, Fournogerakis D, Gauntlett C, et al.:
Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo.
Proc Natl Acad Sci U S A.
2013; 110(29): 11698–703. PubMed Abstract
| Publisher Full Text
| Free Full Text
38.
Pandeló José D, Bartholomeeusen K, da Cunha RD, et al.:
Reactivation of latent HIV-1 by new semi-synthetic ingenol esters.
Virology.
2014; 462-463: 328–39. PubMed Abstract
| Publisher Full Text
| Free Full Text
42.
Darcis G, Kula A, Bouchat S, et al.:
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
PLoS Pathog.
2015; 11(7): e1005063. PubMed Abstract
| Publisher Full Text
| Free Full Text
46.
Cicin-Sain L, Sylwester AW, Hagen SI, et al.:
Cytomegalovirus-specific T cell immunity is maintained in immunosenescent rhesus macaques.
J Immunol.
2011; 187(4): 1722–32. PubMed Abstract
| Publisher Full Text
| Free Full Text
49.
Halper-Stromberg A, Nussenzweig MC:
Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.
J Clin Invest.
2016; 126(2): 415–23. PubMed Abstract
| Publisher Full Text
| Free Full Text
53.
Grupp SA, Kalos M, Barrett D, et al.:
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
N Engl J Med.
2013; 368(16): 1509–18. PubMed Abstract
| Publisher Full Text
| Free Full Text
56.
Haile WB, Gavegnano C, Tao S, et al.:
The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.
Neurobiol Dis.
2016; pii: S0969-9961(16)30028-6. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
57.
Starzl TE, Weil R 3rd, Iwatsuki S, et al.:
The use of cyclosporin A and prednisone in cadaver kidney transplantation.
Surg Gynecol Obstet.
1980; 151(1): 17–26. PubMed Abstract
| Free Full Text
58.
Bunjes D, Hardt C, Röllinghoff M, et al.:
Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.
Eur J Immunol.
1981; 11(8): 657–61. PubMed Abstract
| Publisher Full Text
59.
Andrieu JM, Even P, Venet A, et al.:
Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease.
Clin Immunol Immunopathol.
1988; 47(2): 181–98. PubMed Abstract
| Publisher Full Text
60.
Markowitz M, Vaida F, Hare CB, et al.:
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection.
J Infect Dis.
2010; 201(9): 1298–302. PubMed Abstract
| Publisher Full Text
| Free Full Text
61.
Rizzardi GP, Harari A, Capiluppi B, et al.:
Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.
J Clin Invest.
2002; 109(5): 681–8. PubMed Abstract
| Publisher Full Text
| Free Full Text
62.
Mousseau G, Kessing CF, Fromentin R, et al.:
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
MBio.
2015; 6(4): e00465. PubMed Abstract
| Publisher Full Text
| Free Full Text
71.
Carthagena L, Parise MC, Ringeard M, et al.:
Implication of TRIM alpha and TRIMCyp in interferon-induced anti-retroviral restriction activities.
Retrovirology.
2008; 5: 59. PubMed Abstract
| Publisher Full Text
| Free Full Text
72.
Neagu MR, Ziegler P, Pertel T, et al.:
Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components.
J Clin Invest.
2009; 119(10): 3035–47. PubMed Abstract
| Publisher Full Text
| Free Full Text
73.
Walker JE, Chen RX, McGee J, et al.:
Generation of an HIV-1-resistant immune system with CD34+ hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector.
J Virol.
2012; 86(10): 5719–29. PubMed Abstract
| Publisher Full Text
| Free Full Text
74.
Wright AV, Nuñez JK, Doudna JA:
Biology and Applications of CRISPR Systems: Harnessing Nature's Toolbox for Genome Engineering.
Cell.
2016; 164(1–2): 29–44. PubMed Abstract
| Publisher Full Text
This work was supported by National Institutes of Health grants U19 AI096113 (Martin Delaney Collaboratory of AIDS Researchers for Eradication [CARE] Center Grant, David Margolis, PI), P50 GM082250 (HARC Center Grant, Alan Frankel and Nevan Krogan, coPIs) and AI1049104 (to B.M.P.).
Cary DC and Peterlin BM. Targeting the latent reservoir to achieve functional HIV cure [version 1; peer review: 3 approved] F1000Research 2016, 5(F1000 Faculty Rev):1009 (https://doi.org/10.12688/f1000research.8109.1)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.
Share
Open Peer Review
Current Reviewer Status:
?
Key to Reviewer Statuses
VIEWHIDE
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
I confirm that I have read this submission and believe that I have an
... Continue reading
Competing Interests: No competing interests were disclosed.
Faculty Reviews are commissioned and written by members of the prestigious Faculty Opinions Faculty, and are edited as a service to our readers. In order to make these reviews as comprehensive and accessible as possible, we seek the reviewers’ input before publication. The reviewers’ names and any additional comments they may have are published alongside the review, as is usual on F1000Research.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
I confirm that I have read this submission and believe that I have an
... Continue reading
Competing Interests: No competing interests were disclosed.
Faculty Reviews are commissioned and written by members of the prestigious Faculty Opinions Faculty, and are edited as a service to our readers. In order to make these reviews as comprehensive and accessible as possible, we seek the reviewers’ input before publication. The reviewers’ names and any additional comments they may have are published alongside the review, as is usual on F1000Research.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
I confirm that I have read this submission and believe that I have an
... Continue reading
Competing Interests: No competing interests were disclosed.
Faculty Reviews are commissioned and written by members of the prestigious Faculty Opinions Faculty, and are edited as a service to our readers. In order to make these reviews as comprehensive and accessible as possible, we seek the reviewers’ input before publication. The reviewers’ names and any additional comments they may have are published alongside the review, as is usual on F1000Research.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations -
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Adjust parameters to alter display
View on desktop for interactive features
Includes Interactive Elements
View on desktop for interactive features
Competing Interests Policy
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Examples of 'Non-Financial Competing Interests'
Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.
You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.
You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).
You work at the same institute as any of the authors.
You hope/expect to benefit (e.g. favour or employment) as a result of your submission.
You are an Editor for the journal in which the article is published.
Examples of 'Financial Competing Interests'
You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.
You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.
You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.
Stay Updated
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Comments on this article Comments (0)